Angiotensin II, Human 1PC X 5MG

Description General description Functions in blood pressure maintenance. Stimulates the release of aldosterone from the adrenal gland. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates pp60c-src in vascular smooth muscle cells. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Plays an important role in the regulation of blood pressure. Stimulates the release of aldosterone from the adrenal gland. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Also elicits an increase in voltage-dependent delayed rectifier K+ current in neurons. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates p60c-srcas well as ERK1/2, JNK, and p38 MAP Kinase in vascular smooth muscle cells. Biochem/physiol Actions Cell permeable: no Primary Target adenylate cyclase activity Product does not compete with ATP. Reversible: no Packaging Yes Warning Toxicity: Standard Handling (A) Sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C. Other Notes Zhu, M., et al. 2000. J. Neurophysiol.84, 2494. Natarajan, R., et al. 1999. Hypertension 33, 378. Mazzolai, L., et al. 1998. Hypertension 31, 1324. Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440. Ishida, M., et al. 1995. Circ. Res. 77, 1053. Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.